BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 30626554)

  • 1. Discovery of two novel branched peptidomimetics containing endomorphin-2 and RF9 pharmacophores: Synthesis and neuropharmacological evaluation.
    Zhang T; Han Z; Shi X; Zhao W; Wang Z; Zhang R; Xu B; Zhang M; Zhang Q; Xiao J; Zhu H; Zheng T; Fang Q
    Bioorg Med Chem; 2019 Feb; 27(4):630-643. PubMed ID: 30626554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological characterization of EN-9, a novel chimeric peptide of endomorphin-2 and neuropeptide FF that produces potent antinociceptive activity and limited tolerance.
    Wang ZL; Li N; Wang P; Tang HH; Han ZL; Song JJ; Li XH; Yu HP; Zhang T; Zhang R; Xu B; Zhang MN; Fang Q; Wang R
    Neuropharmacology; 2016 Sep; 108():364-72. PubMed ID: 26970017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BN-9, a chimeric peptide with mixed opioid and neuropeptide FF receptor agonistic properties, produces nontolerance-forming antinociception in mice.
    Li N; Han ZL; Wang ZL; Xing YH; Sun YL; Li XH; Song JJ; Zhang T; Zhang R; Zhang MN; Xu B; Fang Q; Wang R
    Br J Pharmacol; 2016 Jun; 173(11):1864-80. PubMed ID: 27018797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central and peripheral modulation of gastrointestinal transit in mice by DN-9, a multifunctional opioid/NPFF receptor agonist.
    Xu B; Guo Y; Zhang M; Zhang R; Chen D; Zhang Q; Xiao J; Xu K; Li N; Qiu Y; Zhu H; Niu J; Zhang X; Fang Q
    Neurogastroenterol Motil; 2020 Aug; 32(8):e13848. PubMed ID: 32281198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opposite effects of neuropeptide FF on central antinociception induced by endomorphin-1 and endomorphin-2 in mice.
    Wang ZL; Fang Q; Han ZL; Pan JX; Li XH; Li N; Tang HH; Wang P; Zheng T; Chang XM; Wang R
    PLoS One; 2014; 9(8):e103773. PubMed ID: 25090615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involvement of neuropeptide FF receptors in neuroadaptive responses to acute and chronic opiate treatments.
    Elhabazi K; Trigo JM; Mollereau C; Moulédous L; Zajac JM; Bihel F; Schmitt M; Bourguignon JJ; Meziane H; Petit-demoulière B; Bockel F; Maldonado R; Simonin F
    Br J Pharmacol; 2012 Jan; 165(2):424-35. PubMed ID: 21718302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripheral and central sites of action for anti-allodynic activity induced by the bifunctional opioid/NPFF receptors agonist BN-9 in inflammatory pain model.
    Zhang R; Xu B; Zhang MN; Zhang T; Wang ZL; Zhao G; Zhao GH; Li N; Fang Q; Wang R
    Eur J Pharmacol; 2017 Oct; 813():122-129. PubMed ID: 28755985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo effects of μ-opioid receptor agonist/δ-opioid receptor antagonist peptidomimetics following acute and repeated administration.
    Anand JP; Kochan KE; Nastase AF; Montgomery D; Griggs NW; Traynor JR; Mosberg HI; Jutkiewicz EM
    Br J Pharmacol; 2018 Jun; 175(11):2013-2027. PubMed ID: 29352503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VF-13, a chimeric peptide of VD-hemopressin(α) and neuropeptide VF, produces potent antinociception with reduced cannabinoid-related side effects.
    Xu B; Xiao J; Xu K; Zhang Q; Chen D; Zhang R; Zhang M; Zhu H; Niu J; Zheng T; Li N; Zhang X; Fang Q
    Neuropharmacology; 2020 Sep; 175():108178. PubMed ID: 32544481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic administration of the bifunctional opioid/neuropeptide FF receptors agonist BN-9 produced peripheral antinociception in preclinical mouse models of pain.
    Li N; Han ZL; Xu B; Zhang MN; Zhang T; Shi XR; Zhao WD; Guo YY; Zhang QQ; Fang Q
    Eur J Pharmacol; 2018 Oct; 837():53-63. PubMed ID: 30172787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynorphinergic mechanism mediating endomorphin-2-induced antianalgesia in the mouse spinal cord.
    Wu HE; Sun HS; Darpolar M; Leitermann RJ; Kampine JP; Tseng LF
    J Pharmacol Exp Ther; 2003 Dec; 307(3):1135-41. PubMed ID: 14557378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
    Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
    J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of opioid receptors in the spinal antinociceptive effects of neuropeptide FF analogues.
    Gouardères C; Jhamandas K; Sutak M; Zajac JM
    Br J Pharmacol; 1996 Feb; 117(3):493-501. PubMed ID: 8821539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of neuropeptide FF (NPFF)-induced hypothermia and anti-morphine analgesia by RF9, a new selective NPFF receptors antagonist.
    Fang Q; Wang YQ; He F; Guo J; Guo J; Chen Q; Wang R
    Regul Pept; 2008 Apr; 147(1-3):45-51. PubMed ID: 18276024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. OFP011 Cyclic Peptide as a Multifunctional Agonist for Opioid/Neuropeptide FF Receptors with Improved Blood-Brain Barrier Penetration.
    Zhang M; Xu B; Li N; Zhang R; Zhang Q; Chen D; Rizvi SFA; Xu K; Shi Y; Yu B; Fang Q
    ACS Chem Neurosci; 2022 Nov; 13(21):3078-3092. PubMed ID: 36262082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RF313, an orally bioavailable neuropeptide FF receptor antagonist, opposes effects of RF-amide-related peptide-3 and opioid-induced hyperalgesia in rodents.
    Elhabazi K; Humbert JP; Bertin I; Quillet R; Utard V; Schneider S; Schmitt M; Bourguignon JJ; Laboureyras E; Ben Boujema M; Simonnet G; Ancel C; Simonneaux V; Beltramo M; Bucher B; Sorg T; Meziane H; Schneider E; Petit-Demoulière B; Ilien B; Bihel F; Simonin F
    Neuropharmacology; 2017 May; 118():188-198. PubMed ID: 28288815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, modeling, and pharmacological evaluation of UMB 425, a mixed μ agonist/δ antagonist opioid analgesic with reduced tolerance liabilities.
    Healy JR; Bezawada P; Shim J; Jones JW; Kane MA; MacKerell AD; Coop A; Matsumoto RR
    ACS Chem Neurosci; 2013 Sep; 4(9):1256-66. PubMed ID: 23713721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intracerebroventricular administration of CYX-6, a potent μ-opioid receptor agonist, a δ- and κ-opioid receptor antagonist and a biased ligand at μ, δ & κ-opioid receptors, evokes antinociception with minimal constipation and respiratory depression in rats in contrast to morphine.
    Imam MZ; Kuo A; Ghassabian S; Cai Y; Qin Y; Li T; Smith MT
    Eur J Pharmacol; 2020 Mar; 871():172918. PubMed ID: 31958457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endogenous mammalian RF-amide peptides, including PrRP, kisspeptin and 26RFa, modulate nociception and morphine analgesia via NPFF receptors.
    Elhabazi K; Humbert JP; Bertin I; Schmitt M; Bihel F; Bourguignon JJ; Bucher B; Becker JA; Sorg T; Meziane H; Petit-Demoulière B; Ilien B; Simonin F
    Neuropharmacology; 2013 Dec; 75():164-71. PubMed ID: 23911743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential modulation of mu- and delta-opioid antinociception by neuropeptide FF receptors in young mice.
    Desprat C; Zajac JM
    Neuropeptides; 1997 Feb; 31(1):1-7. PubMed ID: 9574828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.